Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Non-intravenous first-line treatment for colorectal cancer

A new combination using uracil/ftorafur/leucovorin and oxaliplatin every 3 weeks is feasible on an outpatient basis, is safe and offers an alternative to the intravenous route, finds January's issue of the British Journal of Cancer.

News image

fiogf49gjkf04

Dr Bennouna and colleagues from France evaluated the efficacy and tolerability of a new combination of uracil/ftorafur/leucovorin and oxaliplatin for colorectal cancer.

The investigative team evaluated 64 patients with metastatic colorectal cancer who had not received prior chemotherapy for metastatic disease.

The team performed a phase 2 trial in 2002.

The patients received uracil/ftorafur 300 mg m2 per day.

Leucovorin was given as 90 mg per day from day 1 to day 14 combined with oxaliplatin 130 mg m2 on day 1, every 3 weeks.

All patients were evaluable for safety analysis and 58 of 64 patients were eligible for efficacy.

Grade 3 diarrhea occurred in only 11% of the patients
British Journal of Cancer

The investigators were reviewed by an independent review committee.

Of the 58 per-protocol defined assessable patients, 1 complete response and 20 partial responses were observed yielding a response rate of 34%.

The median response duration was 9 months.

The median time to progression and the median survival were 6 months, and 18 months, respectively.

The investigative team found that diarrhea and peripheral neuropathy were the most frequent and predictable toxicities.

The team noted that these events were reversible, noncumulative and manageable.

Grade 3 diarrhea occurred in only 11% of the patients.

The investigators observed no grade 4 gastrointestinal toxicity.

The incidence of grade 3 or 4 peripheral neuropathy, according to the National Cancer Institute Common Toxicity Criteria, was 15%.

Hematological toxicity was of mild to moderate intensity with 10% of the patients with Grade 3 or 4 neutropenia without any episode of complication.

Dr Bennounal's team concluded, “The TEGAFOX regimen, a new combination using uracil/ftorafur/leucovorin and oxaliplatin every 3 weeks is feasible on an outpatient basis.”

“The combination is safe and active and may offer a promising alternative to the intravenous route.”

“Nevertheless this efficacy results should be confirmed by randomized phase 3 trials.”

Br J Canc 2006: 94: 69-73
19 January 2006

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us